Details for New Drug Application (NDA): 207922
✉ Email this page to a colleague
NDA 207922 describes DABIGATRAN ETEXILATE MESYLATE, which is a drug marketed by Alembic, Alkem Labs Ltd, Apotex, Breckenridge, Dr Reddys, Hetero Labs Ltd Iii, MSN, and Mylan, and is included in eight NDAs. It is available from eleven suppliers. Additional details are available on the DABIGATRAN ETEXILATE MESYLATE profile page.
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
The generic ingredient in DABIGATRAN ETEXILATE MESYLATE is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
Summary for 207922
| Tradename: | DABIGATRAN ETEXILATE MESYLATE |
| Applicant: | Breckenridge |
| Ingredient: | dabigatran etexilate mesylate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 207922
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 75MG BASE | ||||
| Approval Date: | Dec 19, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | Dec 19, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 110MG BASE | ||||
| Approval Date: | Dec 19, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
